Ruan, D., Dang, Q., Luo, S., Zhao, Y., Nindra, U., Tang, S. Q., Jiang, H., Liu, J., Parsonson, A. O., Morris, M. F., Xie, L., Liang, X., Chen, L., Meng, R., Ding, S., Shi, H., Fang, Y., Pelster, M., Li, Y., Xu, R. (2026). First-in-human study of ALK201, a FGFR2b-targeting antibody-drug conjugate (ADC) for patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.3025